This symposium took place on 29th September 2017, as part of the 47th Annual European Society for Dermatological Research (ESDR) meeting in Salzburg, Austria
Chairpersons: Antonio Costanzo,1 Carle Paul2
Speakers: Antonio Costanzo,1 Carle Paul,2 Flavio Caprioli3,4
1. Dermatology Unit, Department of Biomedical Sciences, Humanitas
University; Skin Pathology Laboratory, Humanitas IRCC, Milan, Italy
2. Department of Dermatology, Paul Sabatier University and Hôpital Larrey, Toulouse, France
3. Department of Pathophysiology and Transplantation, University of Milan; Unit of Gastroenterology
and Endoscopy, Fondazione IRCCS Cà Granda, Ospedale Policlinico of Milan, Milan, Italy
Disclosure: Prof Costanzo has received research support and/or honoraria from Celgene, Janssen, Leo Pharma, AbbVie, Pfizer, and Novartis; he is also a member of the scientific advisory board for Sanofi, Janssen, AbbVie, Pfizer, Novartis, and Celgene. Prof Paul has received research support and/or honoraria or consultation fees from AbbVie, Almirall, Amgen, Astellas, Celgene, GlaxoSmithKline, Eli Lilly and Company, Janssen Cilag, Leo Pharma, Pierre Fabre, Novartis, Pfizer, and Sanofi/Regeneron. Dr Caprioli has received research support and/or honoraria or consultation fees from Takeda, MSD, AbbVie, Mundipharma, Giuliani, Janssen, Celgene, and Roche; he has also participated in company sponsored speakers’ bureau for Takeda, MSD, Abbvie, Mundipharma, and Janssen.
Acknowledgements: Writing assistance was provided by Blair Hesp, ApotheCom, London, UK.
Support: The publication of this article was funded by Janssen. The views and opinions expressed are those of the authors and not necessarily Janssen.
Citation: EMJ. 2017;2:52-58.
Prof Costanzo welcomed attendees to the symposium and outlined the agenda before explaining the autoimmune pathophysiology that underlies psoriasis. Dr Caprioli discussed the role of the T helper (Th)17 cell lineage and its accompanying cytokines in autoimmune diseases. Prof Paul discussed the latest clinical trial data for therapies targeting the interleukin (IL)-17/IL-23 axis in patients with psoriasis, and how this is changing the treatment landscape. The symposium was followed by a question and answer session.
Click here to view the full symposium.
This article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.
The post Linking Pathophysiology to Clinical Options in Psoriasis: New Insights into Interleukin-23 appeared first on European Medical Journal.